Shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) have earned an average recommendation of “Hold” from the seven brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $11.25.

Several equities analysts have weighed in on the company. Maxim Group set a $8.00 price target on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, May 10th. BidaskClub raised Inovio Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, May 18th. ValuEngine raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, May 18th. HC Wainwright set a $13.00 price target on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, May 16th. Finally, Zacks Investment Research raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 3rd.

In other news, CFO Peter Kies sold 35,000 shares of Inovio Pharmaceuticals stock in a transaction on Tuesday, July 10th. The stock was sold at an average price of $4.44, for a total value of $155,400.00. Following the completion of the sale, the chief financial officer now owns 97,088 shares of the company’s stock, valued at $431,070.72. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 9.40% of the stock is owned by insiders.

Several large investors have recently made changes to their positions in the company. Teachers Advisors LLC grew its position in shares of Inovio Pharmaceuticals by 11.2% in the fourth quarter. Teachers Advisors LLC now owns 159,972 shares of the biopharmaceutical company’s stock valued at $661,000 after purchasing an additional 16,104 shares during the period. Levin Capital Strategies L.P. grew its position in shares of Inovio Pharmaceuticals by 80.5% in the second quarter. Levin Capital Strategies L.P. now owns 37,000 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 16,500 shares during the period. Swiss National Bank grew its position in Inovio Pharmaceuticals by 12.8% during the first quarter. Swiss National Bank now owns 156,400 shares of the biopharmaceutical company’s stock valued at $737,000 after acquiring an additional 17,700 shares during the period. New York State Common Retirement Fund grew its position in Inovio Pharmaceuticals by 14.3% during the first quarter. New York State Common Retirement Fund now owns 146,243 shares of the biopharmaceutical company’s stock valued at $689,000 after acquiring an additional 18,300 shares during the period. Finally, Schwab Charles Investment Management Inc. grew its position in Inovio Pharmaceuticals by 8.1% during the second quarter. Schwab Charles Investment Management Inc. now owns 445,846 shares of the biopharmaceutical company’s stock valued at $1,748,000 after acquiring an additional 33,567 shares during the period. 32.67% of the stock is owned by institutional investors and hedge funds.

Shares of INO stock opened at $4.42 on Tuesday. The firm has a market cap of $408.08 million, a P/E ratio of -4.06 and a beta of 1.67. Inovio Pharmaceuticals has a 1 year low of $3.64 and a 1 year high of $7.00.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Read More: Diversification

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.